BiotechTube

BN82451B + Placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Sep 1, 2014 → Mar 31, 2016

NCT ID
NCT02231580

About BN82451B + Placebo

BN82451B + Placebo is a phase 2 stage product being developed by Ipsen for Huntington's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02231580. Target conditions include Huntington's Disease.

What happened to similar drugs?

1 of 2 similar drugs in Huntington's Disease were approved

Approved (1) Terminated (1) Active (0)
✅TetrabenazineLundbeckApproved
❌SAGE-718Supernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02231580Phase 2Terminated

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 2
35
RG6496 + PlaceboRochePhase 1
36
PF-02545920 + PF-02545920PfizerPhase 2
35
20 mg BID of PF-02545920PfizerPhase 2
27
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
35
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
TetrabenazineLundbeckApproved
36
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
29
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
18
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
18
SAGE-718Supernus PharmaceuticalsPhase 3
26
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
29
OMS643762 + PlaceboOmeros CorporationPhase 2
21
VX15/2503 + PlaceboVaccinexPhase 2
25